TargetMol

(-)-Huperzine A

Product Code:
 
TAR-T3026
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T3026-10mg10mg£105.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3026-1mL1 mL * 10 mM (in DMSO)£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3026-25mg25mg£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3026-50mg50mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3026-100mg100mg£282.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3026-200mg200mg£464.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3026-500mg500mg£701.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Huperzine A, an active Lycopodium alkaloid extracted from the traditional Chinese herb, is a potent, selective and reversible acetylcholinesterase (AChE) inhibitor and has been widely used in China for the treatment of Alzheimer's disease (AD).
CAS:
102518-79-6
Formula:
C15H18N2O
Molecular Weight:
242.322
Pathway:
Neuroscience; Membrane transporter/Ion channel; Apoptosis
Purity:
0.9987
SMILES:
[H][C@@]12Cc3[nH]c(=O)ccc3[C@@](N)(CC(C)=C1)C2=CC
Target:
Apoptosis; AChR; AChE; iGluR

References

1. Zhao Q, et al. Eur J Pharmacol, 2002, 455(2-3), 101-107. 2. Zhang HY, et al. Trends Pharmacol Sci, 2006, 27(12), 619-625. 3. Wang R, et al. Acta Pharmacol Sin, 2006, 27(1), 1-26. 4. Zheng CY, et al. J Neurosci Res, 2008, 86(11), 2432-2440.